Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.2.097

Dissolution and Duodenal Permeation Characteristics of Lovastatin from Bile Salt Solid Dispersions  

Chun, In-Koo (College of Pharmacy, Dongduk Women's University)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.2, 2009 , pp. 97-106 More about this Journal
Abstract
Although lovastatin (LS) is widely used in the treatment of hypercholesterolemia, its bioavailability is known to be around 5%. This study was aimed to increase the solubility and dissolution-permeation rates of LS using solid dispersions (SDs) with bile salts. The solubilities of LS in water, aqueous bile salt solutions and non-aqueous vehicles were determined, and effects of bile salts on the cellulose or duodenal permeation of LS from SDs were evaluated using a horizontal permeation system. SDs were prepared at various ratios of LS to carriers, such as sodium deoxycholate (SDC), sodium glycocholate (SGC) and/or 2-hydroxypropyl-$\beta$-cyclodextrin (HPCD). The addition of bile salts (25 mM) in water increased markedly the solubility of LS by the micellar solubilization. Some non-aqueous vehicles were effective in solubilizing LS. From differential scanning calorimetric studies, it was found that the crystallinity of LS in SDs disappeared, indicating a formation of amorphous state. The SDs showed markedly enhanced dissolution compared with those of their physical mixtures (PMs) and drug alone. In the dissolution-permeation studies using a cellulose membrane, the donor and receptor solutions were maintained as a sink condition using pH 7.0 phosphate buffer containing 0.05% sodium lauryl sulfate (SLS). The flux of LS alone was nearly same as that of LS-SDC-HPCD (1:3:6) PM. However, the flux of LS-SDC-HPCD (1:3:6) SD slightly increased compared with drug alone and PM, suggesting that entrapment of LS in micelles does not significantly hinder the permeation across cellulose membrane. In the dissolution-duodenal permeation studies using a LS-HPCD-SDC (1:3:6) SD, the addition of various bile salts in donor solutions (25 mM) enhanced the permeation of LS markedly, and the fluxes were found to be $0.69{\pm}0.41$, $0.87{\pm}0.51$, $0.84{\pm}0.46$, $0.47{\pm}0.17$ and $0.68{\pm}0.32{\mu}g/cm^2/hr$ for sodium cholate (SC), SDC, SGC, sodium taurodeoxycholate (STDC) and sodium taurocholate (STC), respectively. The stepwise increase of donor SGC concentration increased the flux dose-dependently. From the relationship of donor SGC concentration and flux, the concentration of SGC initiating the permeation across the duodenal mucosa was calculated to be 11.1 mM, which is nearly same as the critical micelle concentration (CMC, 11.6 mM) of SGC. However, with no addition of bile salts and below CMC, the permeation was very limited and irratic, indicating that LS itself is very poor permeable. Higher protions of bile salt in SD such as LS-SDC or LS-SGC (1 : 49 and 1 : 69) showed highly promoted fluxes. In conclusion, SD systems with bile salts, which may form their micelles in intestinal fluids, might be a promising means for providing enhanced dissolution and intestinal permeation of practically insoluble and non-absorbable LS.
Keywords
Lovastatin; Solubilization; Duodenal permeation; Bile salts; Solid dispersion;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 H. Sugioka and Y. Moroi, Micelle formation of sodium cholate and solubilization into the micelle, Biochim. Biophys. Acta, 1394, 99-110 (1998).   DOI   ScienceOn
2 S. Reis, C.G. Moutinho, C. Matos, B. de Castro, P. Gameiro and J.J.F.C. Lima, Noninvasive methods to determine the critical micelle concentration of some bile acid salts, Anal. Biochem., 334, 117-126 (2004).   DOI   ScienceOn
3 U. Subuddhi and A.K. Mishra, Micellization of bile salts in aqueous medium: a fluorescence study, Colloids Surf. B: Biointerfaces, 57, 102-107 (2007).   DOI   ScienceOn
4 A. Coello, F. Meijide, E.R. Ninez and J.V. Tato, Aggregation behavior of bile salts in aqueous solutions, J. Pharm. Sci., 85, 9-15 (1996).   DOI
5 K. Matsuoka, M. Maeda and Y. Moroi, Micelle formation of sodium glyco- and taurocholates and sodium glyco- and taurodeoxycholates and solubilization of cholesterol into their micelles, Colloids Surf. B: Biointerfaces, 32, 87-95 (2003).   DOI   ScienceOn
6 K. Matsuoka, M. Suzuki, C. Honda, K. Endo and Y. Moroi, Micellization of conjugated chenodeoxy- and ursodeoxycholates and solubilization of cholesterol into their micelles: comparison with other four conjugated bile salts species, Chem. Phys. Lipids, 139, 1-10 (2006).   DOI   ScienceOn
7 P.M. van Hasselt, G.E.P.J. Janssens, T.K. Slot, M. Van der Ham, T.C. Minderhoud, M. Talelli, L.M. Akkermans, C.J.F. Rijcken and C.F. van Nostrum, The influence of bile salts on the oral bioavailability of vitamin K encapsulated in polymeric micelles, J. Contr. Rel., 133, 161-168 (2009).   DOI   ScienceOn
8 N. Yoshida, Y. Moroi, R. Humphry-Baker and M. Graetzel, Dynamics for solubilization of naphthalene and pyrene into n-decyltrimethylammonium perfluorocarboxylate micelles, J. Phys. Chem. A, 106, 3991-3997 (2002).   DOI   ScienceOn
9 S. Gould and R.C. Scott, 2-Hydroxypropyl-ß-cyclodextrin (HP-ß-CD): a toxicological review, Food Chem. Toxicol., 43, 1451-1459 (2005).   DOI   ScienceOn
10 X. Tan and S. Lindenbaum, Studies on complexation between ß-cyclodextrin and bile salts, Int. J. Pharm., 74, 127-1353 (1991).   DOI   ScienceOn
11 I.K. Chun, D.D. Kim, Y.J. Wang and Y.W. Chien, Permeation enhancement of methionine enkephalin by combinations of enzyme inhibitors and enhancers, S.T.P. Pharma Sci., 6, 148-156 (1996).
12 M.H. Davidson, P. Lukacsko, J.X. Sun, G. Phillips, E. Walters, A. Sterman, R. Niecestro and L. Friedhoff, A multiple-dose pharmacodynamic, safety and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin, Clin. Ther., 24, 112-125 (2002).   DOI   ScienceOn
13 N.Y. Lee and I.K. Chun, Enhanced dissolution of simvastatin by solid dispersion with water-soluble carriers, Dongduk Pharm. Res., 12, 1-12 (2008).
14 M.A. Hammad and B.W. Müller, Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles, Eur. J. Pharm. Biopharm., 46, 361-367 (1998).   DOI   ScienceOn
15 L.A. Woollett, Y. Wang, D.D. Buckley, L. Yao, S. Chin and N. Granholm, Micellar solubilisation of cholesterol is essential for absorption in humans, Gut, 55, 197-204 (2006).   DOI   ScienceOn
16 A.F. Hofmann, Intestinal absorption of bile acids and biliary constituents: the intestinal component of the enterohepatic circulation and the integrated system. In: Physiology of the Gastrointestinal Tract (3rd ed., vol. 2), edited by Johnson L.R., Alpers, D.H., Jacobson, E.D and Walsh, J.H., New York, Raven, 1994, p. 1845-1865
17 A.W. Alberts, Discovery biochemistry and biology of lovastatin, Am. J. Cardiol., 62, J10–J15 (1998).   DOI   ScienceOn
18 A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther., 84, 413-428 (1999).   DOI   ScienceOn
19 G.A. McClelland, R.J. Stubbs, J.A. Fix, S.A. Pogany and G.M., Zentner, Enhancement of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharm. Res., 8, 873-876 (1991).   DOI   ScienceOn
20 R.H. Bradford, C.L. Shear, A.N. Chremos, C.A. Dujovne, F.A. Franklin, R.B. Grillo, J. Higgins, A. Langendörfer, D.T. Nash, J.L. Pool and H. Schnaper, Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up, Am. J. Cardiol., 74, 667-673 (1994).   DOI   ScienceOn
21 R.W. Wang, P.H. Kari, A.Y. Lu, P.E. Thomas, F.P. Guengerich and K.P. Vyas, Biotranformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes, Arch. Biochem. Biophys., 290, 355-361 (1991).   DOI   ScienceOn
22 T. Prueksartanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu and J.H. Lin, Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization, Drug Metab. Dispos., 30, 505-512 (2002).   DOI   ScienceOn
23 M.V.S. Varma, S. Khandavilli, Y. Ashokraj, A. Jain, A. Dhanikula, A. Sood, N.S. Thomas, O.P. Pillai, P. Sharma, R. Gandhi, S. Agrawal, V. Nair and R. Panchagnula, Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research, Curr. Drug Metab., 5, 375-388 (2004).   DOI   ScienceOn
24 P. Sharma, M.V.S. Varma, H.P.S. Chawla and R. Panchagnula, Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers, Il Pharmaco, 60, 884-893 (2005).
25 B.K. Kang, B.Y. Yoon, K.S. Seo, S.Y. Jeung, J.H. Kil, G. Khang, H.B. Lee and S.H. Cho, Preparation of solid dosage form containing SMEDDS of simvastatin by microencapsulation. J. Kor. Pharm. Sci., 33, 121-127 (2003).   과학기술학회마을
26 S. Comini, P. Olivier, M. Riottot and D. Duhamel, Interaction of ß-cyclodextrin with bile acids and their competition with vitamins A and D3 as determined by 1HNMR spectrometry, Clin. Chem. Acta, 228, 181-194 (1994).   DOI   ScienceOn
27 F.G.J. Poelma, R. Breas and J.J. Tukker, Intestinal absorption of drugs. IV. the influence of taurocholate and L-cysteine on the barrier function of mucus, Int. J. Pharm., 64, 161-169 (1990).   DOI   ScienceOn
28 A.F. Hofmann and K.J. Mysels, Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH and Ca2+ ions, J. Lipid Res., 33 617-626 (1992).
29 Y. Shitara and Y. Sugiyama, Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions, Pharmacol. Ther., 112, 71-105 (2006).   DOI   ScienceOn
30 L. Forsgren, Studies on the intestinal absorption of labelled fat-soluble vitamins (A, D, E, and K) via the thoracic-duct lymph in the absence of bile in man, Acta Chir. Scand. Suppl., 399, 1-29 (1969).
31 G.L. Amidon, H. Lennernas, V.P. Shah and J.R. Crison, A theoretical basis for biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413-420 (1995).   DOI   ScienceOn
32 M.A. Vandelli, G. Salvioli, A. Mocci, R. Panini, L. Malmusi and F. Forni, 2-Hydroxypropyl-ß-cyclodextrin complexation with ursodeoxycholic acid, Int. J. Pharm., 118, 77-83 (1995).   DOI   ScienceOn
33 R. Ninomiya, K. Matsuoka and Y. Moroi, Micelle formation of sodium deoxycholate and solubilization into the micelles: comparison with other unconjugated bile salts, Biochem. Biophys. Acta, 1634, (2003).   DOI   ScienceOn
34 J.R. Crouse III, P. Lukacsko and R. Niecestro, The Lovastatin Extended-Release Study Group, Dose response, safety and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia, Am. J. Cardiol., 89, 226-229 (2002).   DOI   ScienceOn
35 E. Wang, C.N. Casciano, R.P. Crement and W.W. Johnson, HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein, Pharm. Res., 18, 800-806 (2001).   DOI   ScienceOn